Ethical considerations in leaping from bench to bedside

Science

Volumn 285, Issue 5436, 1999, Pages 2071-2072

  Sugarman, Jeremy ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL MEDICINE; ETHICS; EXPERIMENTATION; HUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SAFETY; SCIENCE; SHORT SURVEY; ALPHA THALASSEMIA; ANIMAL; BIOMEDICAL AND BEHAVIORAL RESEARCH; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; FEMALE; FETUS DISEASE; GENE THERAPY; GENE TRANSFER; GENETICS AND REPRODUCTION; HUMAN EXPERIMENT; INFORMED CONSENT; MEDICAL ETHICS; METHODOLOGY; NOTE; PREGNANCY; PREGNANT WOMAN; STANDARD;

ADENOSINE DEAMINASE;

BIOMEDICAL AND BEHAVIORAL RESEARCH; GENETICS AND REPRODUCTION;

ADENOSINE DEAMINASE; ALPHA-THALASSEMIA; ANIMALS; CLINICAL TRIALS; ETHICS, MEDICAL; FEMALE; FETAL DISEASES; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMAN EXPERIMENTATION; HUMANS; INFORMED CONSENT; NONTHERAPEUTIC HUMAN EXPERIMENTATION; PREGNANCY; PREGNANT WOMEN; RESEARCH DESIGN; SAFETY; SEVERE COMBINED IMMUNODEFICIENCY;

EID: 0032873764     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.285.5436.2071     Document Type: Short Survey

References (17)

1. S. E. Lederer, Subjected to Science (Johns Hopkins Univ. Press, Baltimore, MD, 1995).
2. E. T. Juengst, Hum. Gene Ther. 1, 425 (1990).
3. E. Zanjani and W. F. Anderson, Science 285, 2084 (1999). See also http://strategicresults.com/nih/ gtpc3/index.html.
4. J. F. Fletcher and G. Richter, Hum. Gene Ther. 7, 1605 (1996).
5. J. Sugarman, "Ethical questions related to the prospect of in utero gene transfer experiments," in Gene Therapy Policy Conference Report: Prenatal Gene Transfer Research (NIH, Bethesda, MD, 1999), in press.
6. World Medical Association, Declaration of Helsinki (1996).
7. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, Research on the fetus, in A. Jonsen, R. Veatch, R. L. Walters, Eds., Source Book in Bioethics: A Documented History (Georgetown Press, Washington, DC, 1998), p. 29.
8. 45 Code of Federal Regulations (C.F.R.) 46, subpart B.
9. Permissible medical experiments, Trials of War Criminals before the Nuernberg Military Tribunals under Control Council Law No. 10: Nuernberg, October 1946-1949, 2 (U.S. Government Printing Office, Washington, DC, n.d.), pp. 181-182.
10. J. P. Kahn, A. M. Mastroianni, J. Sugarman, Eds., Beyond Consent: Seeking Justice in Research (Oxford Univ. Press, New York, 1998).
11. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, Belmont Report (Department of Health, Education and Welfare, 1979).
12. 45 C.F.R. 46; 21 C.F.R. 312; Center for Drug Evaluation Research, Center for Biologics Evaluation and Research, Guidance for Industry: Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products (U.S. Food and Drug Administration, Washington, DC, 1995).
13. P. Appelbaum, L. Roth, C. Lidz. Int. J. Law Psychiatry 5, 319 (1982).
14. _, Hastings Cent. Rep. 17, 20 (1987).
15. J. Sugarman et al., IRB: Rev. Hum. Subj. Res. 20, 1 (1998).
16. N. M. P. King, Hum. Gene Ther. 10, 133 (1999).
17. R. Buckley et al., N. Engl. J. Med. 340, 508 (1999).